PeptAid is developing a novel peptide-based immunotherapy to treat glioblastoma, the most aggressive and currently incurable brain tumor. Our lead candidate, I49, is a synthetic peptide that targets SPP1, a key driver of immune suppression and tumor progression. By blocking SPP1, I49 reprograms immu... Read more
Org chart
Collapse
No reports!
Teams
This company has no teams yet
Offices
This company has no offices yet
